NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release fourth quarter 2025 results on Wednesday, February 25, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 330912. For international participants, ...

Teladoc Health, Inc. (NYSE:TDOC) is one of the stocks Jim Cramer shared his opinion on. When a caller mentioned that they hold the stock in an IRA and have experienced a loss of nearly 96%, Cramer commented: Just get rid of it. I don’t see any reason to own it… There’s a lot of companies that are in that business. I’m sorry. I wish it were good… But you know, wishing don’t cut it. Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels Teladoc Health, Inc. (NYSE:TDOC) p ...

Teladoc stock price crashed to a record low as demand for its services waned after the pandemic. It plunged to a low of $5.74, down sharply from the all-time high of $308, with its market capitalizati... ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. 2026 is an “execution year” for Teladoc Health, CEO Chuck Divita told Healthcare Dive. The telehealth company has spent the past year focusing on a strategy shift, prioritizing international expansion, improving operating efficiency, better leveraging its mental health assets and enhancing its integrated care business. The goal is to deliver sustainable lon ...

Medicare is making a big change that will kick in at the end of the month. Through Jan. 30, Medicare will cover telehealth services, delivered to you wherever you are, including in your home. But as of the next day, coverage will end -- unless you live in a rural area and go to a medical facility for the appointment. There are a few other exceptions, but overall, Medicare is no longer broadly covering telehealth services as it did in the past. Considering this shift, will Teladoc Health (NYSE: TDOC) stoc ...

Key Points Medicare will no longer cover telemedicine services for many patients. This change will affect Teladoc Health, which was already struggling. Doximity might be less affected, but its prospects look dim as well. 10 stocks we like better than Teladoc Health › Telehealth services are convenient. There is nothing quite like being able to get some medical care, albeit virtual, from the comfort of one's home. Telehealth likely saves physicians and patients time and money. However, none of t ...

Group 1: Sarepta Therapeutics - Sarepta Therapeutics' shares declined by over 80% last year due to safety concerns surrounding its key product, Elevidys, which targets Duchenne muscular dystrophy (DMD) [3][4] - The company had to include a boxed warning for potential liver injury and restrict access to Elevidys after two patients died from liver failure [4][6] - For 2025, Sarepta expects revenue of $1.86 billion, a decline from $1.9 billion in the previous year, indicating a drop in demand for its medicine [6] - Despite efforts to develop new medicines and potential clinical progress, these products are not expected to impact financial performance in the near term [6][7] - Concerns remain regarding the safety of Sarepta's pipeline products, which could further affect investor confidence [7] Group 2: Teladoc Health - Teladoc Health has faced slow to non-existent revenue growth and accumulated net losses in recent years [8] - Increased competition in the telemedicine space has undermined Teladoc's market share, particularly affecting its virtual therapy platform, BetterHelp, which has seen a decline in paying members [9][10] - The company is attempting to improve its situation by seeking broader insurance coverage for BetterHelp and expanding internationally, but challenges similar to those faced domestically are anticipated abroad [12][13] - Teladoc's market cap stands at $1.1 billion, with a current price of $6.16, reflecting ongoing struggles in the market [11][12]

Core Viewpoint - The article provides insights into the investment landscape, emphasizing the importance of thorough research and independent verification of information before making investment decisions [2][3]. Group 1: Company Analysis - The article does not mention specific companies or their financial performance, focusing instead on general investment advice and the need for due diligence [2][3]. Group 2: Industry Insights - The content highlights the inherent volatility and risks associated with stock investments, suggesting that past performance is not indicative of future results [3]. - It underscores the necessity for investors to assess their financial circumstances and conduct comprehensive research before engaging in stock trading [2].

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no financial interest in the companies mentioned, ensuring an unbiased perspective [1]. Group 2 - The article stresses that past performance is not indicative of future results, cautioning readers against relying solely on historical data [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article highlights that the analysts involved may not be licensed or certified, which could affect the reliability of the information provided [3].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]